Nintx and Centroflora pinpointed an herbaceous plant from the Amazon rainforest to tackle a global multifactorial disease in a undisclosed therapeutic area
Nintx and Grupo Centroflora put a new spin on a raw material from the Brazilian biodiversity to co-develop an innovative multi-target therapy. The companies pinpointed an herbaceous plant from the Amazon rainforest to tackle a global multifactorial disease in an undisclosed therapeutic area. “Centroflora has know-how in the cultivation and extraction processes for this herbaceous plant, but Nintx has put together a novel value proposition to generate a therapy for an indication very different than the established ones. We are sure that a fantastic therapy will emerge from this collaboration that will not only benefit patients, but also family farmers and the environment”, said Peter Andersen, CEO, Centroflora. “Nintx has deep knowledge in discovery and development, and Centroflora is a worldwide leader in the manufacturing of plant-based natural products. This new agreement will strengthen our ties, which started in the structuring of Nintx’s xGIbiomics® lab, and help to illustrate how Brazil can be positioned as a serious R&D player worldwide”, stated Dr. Miller Freitas, CEO, Nintx.
To have access to the full content, check us out on LinkedIn. https://www.linkedin.com/feed/update/urn:li:activity:7025829108785778688/
Comments